SCHIZOPHRENIA
Enrollment Pending for Phase 2 Study
Enrollment is pending for our Phase 2 study to evaluate the efficacy, safety, tolerability, and pharmacodynamics of SPG302 in adults with a primary diagnosis of schizophrenia.
For Our Upcoming Clinical Trial in Australia:
NCT06442462
Status: not yet recruiting; please continue to check the status at ClinicalTrials.gov
Location
MAPrc, Melbourne VIC, Australia
Contact: Emorfia Gavrilidis at MAPrc
emmy.gavrilidis@monash.edu
For additional information, visit ClinicalTrials.gov
